Top 50 Biotech Innovators Highlighted in Recent IPO Filing: UnknownBio, XingMou Bio, and ZhenXing Pharma Advance Clinical Pipelines
Xbiome
AI Drug Developer for Gut Microbiota
StarryGene
Gene Therapy Drug Developer
1
Xbiome's XA-511 Strain Granted Another National Invention Patent in China
2
StarryGene Completes A2 Round Financing Worth Tens of Millions of RMB
3
Zhenxing Pharmaceutical's SM-1 Project Successfully Selected for ESMO European Society for Medical Oncology Annual Meeting
Time
October 15, 2025 (Wednesday) 14:30--17:30
Location
Shenzhen Airport DoubleTree by Hilton Hotel
(No. 66, Hangcheng Avenue, Bao'an District, Shenzhen City, Guangdong Province, China)
Scan the code to register for participation / exhibition
PART.1
Xbiome
Recently, Top 50 Leading Enterprises in Biotechnology Innovation of the 7th Edition —— Xbiome Co. Ltd.Breakthrough progress has been made in the field of tumor disease treatment.Xbiome's Isolated and Developed Strain XA-511 (Megasphaera indica) Officially Granted National Patent Authorization, the patent name is "Application of Giant Spherical Bacteria in the Preparation of Anti-Cancer Drugs," with the patent number ZL 202310941665.1.
Xbiome, founded in 2017, owns a leading AI microbiome research and industrial transformation platform, strategically focusing on FMT, drug discovery, and probiotics. In drug discovery, the team has completed layouts in areas such as oncology, digestive diseases, immune-related diseases, and urological diseases, with four pipelines now in clinical stages, two of which have entered phase II clinical trials. Regarding FMT, Xbiome has collaborated with nearly 20 well-known tertiary hospitals in China, including Peking University Cancer Hospital and Peking Union Medical College Hospital, to conduct gut microbiome clinical research across various indications. Additionally, they have developed the AI-FMT personalized precision treatment project targeting the broader health market, benefiting patients with chronic diseases and suboptimal health conditions. In the field of probiotics, Xbiome has successfully completed commercial collaborations and transformations with several top domestic and international health companies while continuing to advance the development of proprietary strains.
PART.2
StarryGene
Recently,Top 50 Emerging Companies in Biotech Innovation for the 7th Year ——StarryGene Completes RMB Tens of Millions in A2 Round Financing, this round of financing was jointly completed by Kaitai Venture Capital, Guoke Venture Capital, and others.
The funds from this round of financing will provide important financial support for StarryGene's product development, primarily focusing on conducting Phase II clinical trials for the company’s core product—wAMD product XMVA09—as well as simultaneously advancing the pharmaceutical, preclinical research, and IIT clinical trials for the dAMD and TED pipelines.
StarryGene is a high-tech enterprise that develops cutting-edge gene editing technologies and gene therapy products for ophthalmic diseases, focusing on the development of ophthalmic gene therapy drugs. The core team of StarryGene is a doctoral entrepreneurial team led by a "Distinguished Young Scholar," possessing two key technology platforms on the R&D side: the AAV-Antibody Gene Drug Platform (including the bispecific antibody optimization platform and the capsid screening platform) and the gene editing platform.
PART.3
Zhenxing Medicine
Top 50 Emerging Companies in Biotechnology Innovation – 6th EditionZhenxing Pharmaceutical's Self-Developed Global New Target, Broad-Spectrum Oral Small Molecule Anti-Cancer Drug SM-1 for the Treatment of Recurrent High-Grade Glioma (RHGG) Successfully Entered the "2025 European Society for Medical Oncology (ESMO)" Shortlist and Was Approved for Oral Presentation。
This successful selection marks that the SM-1 project has received significant attention, and its clinical research achievements have made a major breakthrough in gaining international recognition for scientific rigor, innovation, and clinical value. This not only provides new ideas and directions for cancer treatment but also lays a solid scientific theoretical foundation for Zhenxing Pharmaceuticals to expand into the global market.
About the Top 50 Biotech Innovation Selection
The Top 50 Biotechnology Innovation Enterprises in the Guangdong-Hong Kong-Macao Greater Bay Area selection, hosted by the Zhongchuang Industry Research Institute and organized by the Guangdong Medical Valley, has been successfully held for eight consecutive sessions. As the largest and most dynamic multilateral resource exchange and sharing industrial innovation ecosystem in the Greater Bay Area's biopharmaceuticals industry, it aims to discover China's future biotech unicorns. The platform provides biotech companies with an integrated industrial hub connecting enterprises, academia, government, and other resources, accelerating the development of China's biopharmaceuticals industry through industrial collaboration and resource aggregation.
For industry communication groups, cooperation, contributions, etc.
Please scan the QR code to add
